{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:55:07Z","timestamp":1788245707482,"version":"build-2803163510"},"reference-count":49,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"unspecified","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Acepodia","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,6,16]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Targeting epidermal growth factor receptor (EGFR) has become a strategic approach in cancer therapy, using various modalities including chimeric antigen receptor (CAR)-\u03b1\u03b2T cell therapies. Despite significant advancements in autologous CAR-\u03b1\u03b2T cell therapies in B-cell lymphoma, current cell therapies face challenges such as potential risks associated with genetic engineering, waiting time and high costs of autologous CAR-\u03b1\u03b2T cell therapies. Innovations in click chemistry and bioorthogonal chemistry have enabled the development of antibody-cell conjugation (ACC) technology, which links cancer-targeting antibodies to immune cells without genetic modifications, potentially providing a safer profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, we introduce ACE2016, an innovative allogeneic cell therapy targeting EGFR. ACE2016 is generated by ACC technology to conjugate donor-derived \u03b3\u03b42 T cells with the EGFR-specific antibody cetuximab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our preclinical studies demonstrate that ACE2016 exhibits superior cytotoxicity against various EGFR-expressing cancer cell lines and minimal cytotoxic effects on normal cells. Mechanistic studies revealed that ACE2016 enhances cytotoxicity through increased capacity towards EGFR-expressing cancer cells, enhanced levels of cytotoxic cytokines and recruitment of peripheral cytotoxic cells, reflecting significant tumor suppression and prolonged survival in ACE2016-treated groups without causing treatment-related toxicity in vivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings support the clinical potential of ACE2016 as an off-the-shelf \u03b3\u03b42 T-cell therapy for EGFR-expressing cancers, offering a combination of specificity, scalability, and safety in the development of solid tumor therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2024-010500","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T09:40:14Z","timestamp":1752572414000},"page":"e010500","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Allogeneic cetuximab-armed gamma delta T cells using antibody-cell conjugation technology for the treatment of EGFR-expressing solid tumors"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct04319757","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05653271","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06415487","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04319757","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05653271","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05387265","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04903795","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05099549","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7790-3443","authenticated-orcid":false,"given":"Hao-Kang","family":"Li","sequence":"first","affiliation":[{"name":"Acepodia Biotech Inc, Alameda, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai-Sheng","family":"Wu","sequence":"additional","affiliation":[{"name":"Acepodia Biotech Inc, Alameda, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Ru","sequence":"additional","affiliation":[{"name":"Acepodia Biotech Inc, Alameda, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chiu","family":"Kuo","sequence":"additional","affiliation":[{"name":"Acepodia Biotech Inc, Alameda, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Yun","family":"Lee","sequence":"additional","affiliation":[{"name":"Acepodia Biotech Inc, Alameda, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Ju","family":"Leng","sequence":"additional","affiliation":[{"name":"Acepodia Biotech Inc, Alameda, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chun","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Acepodia Biotech Inc, Alameda, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Jung","family":"Chiang","sequence":"additional","affiliation":[{"name":"Acepodia Biotech Inc, Alameda, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zih-Fei","family":"Cheng","sequence":"additional","affiliation":[{"name":"Acepodia Biotech Inc, Alameda, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Liang","family":"Lin","sequence":"additional","affiliation":[{"name":"Acepodia Biotech Inc, Alameda, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Chia","family":"Hsiao","sequence":"additional","affiliation":[{"name":"Acepodia Biotech Inc, Alameda, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8577-2461","authenticated-orcid":false,"given":"Sai-Wen","family":"Tang","sequence":"additional","affiliation":[{"name":"Acepodia Biotech Inc, Alameda, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"2025100305261844000_13.7.e010500.1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-008-7440-8"},{"key":"2025100305261844000_13.7.e010500.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2022.05.011"},{"key":"2025100305261844000_13.7.e010500.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.02.003"},{"key":"2025100305261844000_13.7.e010500.4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.01249","article-title":"The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells","volume":"10","author":"Cai","year":"2020","journal-title":"Front Oncol"},{"key":"2025100305261844000_13.7.e010500.5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.737311","article-title":"The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies","volume":"12","author":"Baysal","year":"2021","journal-title":"Front Immunol"},{"key":"2025100305261844000_13.7.e010500.6","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","article-title":"BL-B01D1, a first-in-class EGFR\u2013HER3 bispecific antibody\u2013drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study","volume":"25","author":"Ma","year":"2024","journal-title":"Lancet Oncol"},{"key":"2025100305261844000_13.7.e010500.7","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1001\/jamaoncol.2022.0503","article-title":"Evaluation of Safety of Treatment With Anti-Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors: A Phase 1 Nonrandomized Clinical Trial","volume":"8","author":"Qiu","year":"2022","journal-title":"JAMA Oncol"},{"key":"2025100305261844000_13.7.e010500.8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40164-021-00250-1","article-title":"Recent advances and challenges of bispecific antibodies in solid tumors","volume":"10","author":"Wu","year":"2021","journal-title":"Exp Hematol Oncol"},{"key":"2025100305261844000_13.7.e010500.9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0432"},{"key":"2025100305261844000_13.7.e010500.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2020.04.088"},{"key":"2025100305261844000_13.7.e010500.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02893-z"},{"key":"2025100305261844000_13.7.e010500.12","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41420-024-01815-9","article-title":"Breakthrough of solid tumor treatment: CAR-NK immunotherapy","volume":"10","author":"Wang","year":"2024","journal-title":"Cell Death Discov"},{"key":"2025100305261844000_13.7.e010500.13","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0051-2"},{"key":"2025100305261844000_13.7.e010500.14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/d41586-024-01215-0","article-title":"Do cutting-edge CAR-T-cell therapies cause cancer? What the data say","volume":"629","author":"Willyard","year":"2024","journal-title":"Nature New Biol"},{"key":"2025100305261844000_13.7.e010500.15","doi-asserted-by":"publisher","DOI":"10.1002\/anie.200900942"},{"key":"2025100305261844000_13.7.e010500.16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jcyt.2020.01.003","article-title":"A novel antibody-cell conjugation method to enhance and characterize cytokine-induced killer cells","volume":"22","author":"Frank","year":"2020","journal-title":"Cytotherapy"},{"key":"2025100305261844000_13.7.e010500.17","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112724","article-title":"A Novel off-the-Shelf Trastuzumab-Armed NK Cell Therapy (ACE1702) Using Antibody-Cell-Conjugation Technology","volume":"13","author":"Li","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025100305261844000_13.7.e010500.18","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15194844","article-title":"A Novel Allogeneic Rituximab-Conjugated Gamma Delta T Cell Therapy for the Treatment of Relapsed\/Refractory B-Cell Lymphoma","volume":"15","author":"Li","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025100305261844000_13.7.e010500.19","doi-asserted-by":"publisher","DOI":"10.1021\/la900150n"},{"key":"2025100305261844000_13.7.e010500.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.10.006"},{"key":"2025100305261844000_13.7.e010500.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2004.08.008"},{"key":"2025100305261844000_13.7.e010500.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-1759(03)00265-5"},{"key":"2025100305261844000_13.7.e010500.23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2014.00618","article-title":"\u03b3\u03b4 T Cell-Mediated Antibody-Dependent Cellular Cytotoxicity with CD19 Antibodies Assessed by an Impedance-Based Label-Free Real-Time Cytotoxicity Assay","volume":"5","author":"Seidel","year":"2014","journal-title":"Front Immunol"},{"key":"2025100305261844000_13.7.e010500.24","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s43586-021-00028-z","article-title":"Bioorthogonal chemistry","volume":"1","author":"Scinto","year":"2021","journal-title":"Nat Rev Methods Primers"},{"key":"2025100305261844000_13.7.e010500.25","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24010172","article-title":"Click Chemistry as a Tool for Cell Engineering and Drug Delivery","volume":"24","author":"Takayama","year":"2019","journal-title":"Molecules"},{"key":"2025100305261844000_13.7.e010500.26","doi-asserted-by":"publisher","DOI":"10.1039\/c9sc03368h"},{"key":"2025100305261844000_13.7.e010500.27","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.01362","article-title":"Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment","volume":"10","author":"van der Schans","year":"2020","journal-title":"Front Oncol"},{"key":"2025100305261844000_13.7.e010500.28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.954235","article-title":"Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies","volume":"13","author":"Xiao","year":"2022","journal-title":"Front Immunol"},{"key":"2025100305261844000_13.7.e010500.29","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41392-023-01646-7","article-title":"Anti-PD-1 antibody armored \u03b3\u03b4 T cells enhance anti-tumor efficacy in ovarian cancer","volume":"8","author":"Wang","year":"2023","journal-title":"Sig Transduct Target Ther"},{"key":"2025100305261844000_13.7.e010500.30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-3-030-49270-0_5","article-title":"\u03b3\u03b4 T Cells in Tumor Microenvironment","volume":"1273","author":"Imbert","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"2025100305261844000_13.7.e010500.31","doi-asserted-by":"publisher","DOI":"10.1038\/nri3904"},{"key":"2025100305261844000_13.7.e010500.32","doi-asserted-by":"crossref","first-page":"334","DOI":"10.37349\/ei.2022.00054","article-title":"Allogeneic gamma delta T cells as adoptive cellular therapy for hematologic malignancies","volume":"2","author":"Jhita","year":"2022","journal-title":"Explor Immunol"},{"key":"2025100305261844000_13.7.e010500.33","doi-asserted-by":"crossref","DOI":"10.3390\/cells9051305","article-title":"\u03b3\u03b4 T Cells: The Ideal Tool for Cancer Immunotherapy","volume":"9","author":"Yazdanifar","year":"2020","journal-title":"Cells"},{"key":"2025100305261844000_13.7.e010500.34","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41392-023-01653-8","article-title":"\u03b3\u03b4 T cells: origin and fate, subsets, diseases and immunotherapy","volume":"8","author":"Hu","year":"2023","journal-title":"Sig Transduct Target Ther"},{"key":"2025100305261844000_13.7.e010500.35","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103811","article-title":"A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy","volume":"99","author":"Ayati","year":"2020","journal-title":"Bioorg Chem"},{"key":"2025100305261844000_13.7.e010500.36","doi-asserted-by":"crossref","DOI":"10.3390\/cells10051206","article-title":"Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review","volume":"10","author":"Karlsen","year":"2021","journal-title":"Cells"},{"key":"2025100305261844000_13.7.e010500.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.120082"},{"key":"2025100305261844000_13.7.e010500.38","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1135","article-title":"EGFR-targeted CAR-T cells are potent and specific in suppressing triple-negative breast cancer both in vitro and in vivo","volume":"9","author":"Xia","year":"2020","journal-title":"Clin Transl Immunology"},{"key":"2025100305261844000_13.7.e010500.39","doi-asserted-by":"crossref","DOI":"10.3390\/antib8030041","article-title":"Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells","volume":"8","author":"Strohl","year":"2019","journal-title":"Antibodies (Basel)"},{"key":"2025100305261844000_13.7.e010500.40","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.apsb.2024.01.009","article-title":"Bispecific antibody drug conjugates: Making 1+1>2","volume":"14","author":"Gu","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"2025100305261844000_13.7.e010500.41","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41423-020-0417-8","article-title":"Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics","volume":"17","author":"Li","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"2025100305261844000_13.7.e010500.42","doi-asserted-by":"crossref","DOI":"10.1080\/15384047.2024.2356820","article-title":"T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer","volume":"25","author":"Palecki","year":"2024","journal-title":"Cancer Biol Ther"},{"key":"2025100305261844000_13.7.e010500.43","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2014.00636","article-title":"Clinical applications of gamma delta T cells with multivalent immunity","volume":"5","author":"Deniger","year":"2014","journal-title":"Front Immunol"},{"key":"2025100305261844000_13.7.e010500.44","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.93179","article-title":"Adoptively transferred V\u03b39V\u03b42 T cells show potent antitumor effects in a preclinical B cell lymphomagenesis model","volume":"2","author":"Zumwalde","year":"2017","journal-title":"JCI Insight"},{"key":"2025100305261844000_13.7.e010500.45","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.2022016204","article-title":"Genome-edited allogeneic donor 'universal' chimeric antigen receptor T cells","volume":"141","author":"Qasim","year":"2023","journal-title":"Blood"},{"key":"2025100305261844000_13.7.e010500.46","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2020.00148","article-title":"Gene-Editing Technologies Paired With Viral Vectors for Translational Research Into Neurodegenerative Diseases","volume":"13","author":"Rittiner","year":"2020","journal-title":"Front Mol Neurosci"},{"key":"2025100305261844000_13.7.e010500.47","doi-asserted-by":"crossref","DOI":"10.1126\/science.aay5516","article-title":"Butyrophilin 2A1 is essential for phosphoantigen reactivity by \u03b3\u03b4 T cells","volume":"367","author":"Rigau","year":"2020","journal-title":"Science"},{"key":"2025100305261844000_13.7.e010500.48","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-021-00576-0"},{"key":"2025100305261844000_13.7.e010500.49","doi-asserted-by":"publisher","DOI":"10.1615\/critrevimmunol.2015013607"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-010500","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:26:29Z","timestamp":1759494389000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-010500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":49,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,15]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/jitc-2024-010500"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-010500","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}